Structure Therapeutics Inc.

GPCR Nasdaq SEC CIK 1888886
Follow Structure Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$144.8M −120.3% vs same quarter last year
EPS, diluted −$0.66 −78.4% vs same quarter last year
Operating cash flow −$101.7M −99.4% vs same quarter last year
Operating income −$156.3M −111.9% vs same quarter last year
Net income by quarter
−$36.5M
−$46.8M
−$61.7M
−$65.7M
$33M
−$76M
−$106.2M
−$144.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$150M−$100M−$50M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$141.2M
FY24−$122.5M
FY23−$89.6M
FY22−$51.3M
FY21-
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$225.8M
FY24−$117.9M
FY23−$81.7M
FY22−$46.3M
FY21-